Early identification and referral of patients with inflammatory back pain (IBP) to rheumatologists for further assessment is imperative in ensuring those with axial spondyloarthritis (axSpA) receive timely intervention. In this interview, Associate Professor Dr Fariz Yahya shared his insights into the development, use and importance of the primary care physician-targeted IBP referral algorithm, which had been published in Malaysian Family Physician
Psoriasis (PsO) is a lifelong, systemic inflammatory disease associated with multiple comorbidities that extends beyond just the surface of the skin.1 Recently, MIMS Doctor spoke to Dr Bong Jan Ling, a Consultant Dermatologist at Sunway Medical Centre to gather her thoughts on the current treatment landscape of PsO, specifically the risk factors of developing psoriatic arthritis (PsA), a condition closely related to PsO, and how the coronavirus disease 2019 (COVID-19) pandemic may have impacted the management of PsO.
At the recent Malaysia MPN Expert Forum, Dr Harry Gill, Clinical Assistant Professor at the University of Hong Kong, presented a review of the current treatment landscape in myelofibrosis (MF), along with a detailed look at the optimization of Jakavi® (ruxolitinib), Novartis in MF management. The forum was organized in collaboration between Novartis and the Malaysian Society of Haematology (MSH).
Cardiovascular disease (CVD) is a common comorbidity in diabetes mellitus (DM) and its prevalence is on the rise. Studies have reported that several factors including oxidative stress, low-grade inflammation, endothelial dysfunction and autonomic neuropathy are often present in patients with DM, and may directly contribute to the increased prevalence of myocardial infarction (MI), coronary revascularisation, stroke and congestive heart failure (HF).1,2 The presence of both DM and CVD in patients increases the risk of mortality and morbidity among men and women alike.
Dr. Ameet Patki, Dr. Prakash Mayandi, 20220322000000
Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.
Severe Asthma Masterclass, a local national virtual event held under the auspices of the Malaysian Thoracic Society, was conducted to provide a robust platform for an in-depth discussion on severe asthma management. This event was led by two renowned clinical experts in respiratory specialty, Associate Professor Dr Pang Yong Kek and Professor Norbert Berend who have vast experience in severe asthma management. Key topics on severe asthma prevalence, diagnosis, treatment and management, and role of eosinophils in the paradigm of severe asthma were presented and discussed during this event, providing a comprehensive overview on severe asthma management and the crucial role of biologics in treating severe eosinophilic asthma.
At the recent 18th Annual Scientific Meeting of the Malaysian Society of Haematology (MSH), Professor Dr Claire Harrison, clinical director at Guy’s and St Thomas’ NHS Foundation Trust, UK, presented an overview of myelofibrosis (MF) management considerations from a patient-centric perspective and the therapeutic role of ruxolitinib (Jakavi®, Novartis). The satellite symposium was organized by Novartis in collaboration with the MSH.